EditForce
EditForce is a venture company originating from Kyushu University, utilizing proprietary RNA editing technology to create new standards in medicine, industry, and agriculture. The company aims to develop safe and innovative gene therapies targeting various diseases, including neurodegenerative, muscular, and rare diseases, by applying PPR platform technology to reduce genomic damage during treatment. Their mission is to deliver these therapies worldwide and create new value across multiple fields.
Industries
Nr. of Employees
small (1-50)
EditForce
Patents
Products
Lead therapeutic program targeting myotonic dystrophy type 1 (DM1) using RNA-targeting molecules
A preclinical development program that uses sequence-specific RNA-binding molecules to bind toxic CUG-repeat DMPK mRNA and inhibit pathogenic RNA mechanisms; delivery approaches include systemic AAV vectors.
EF-210
EF-210 is a recombinant AAV gene therapy delivering the CUG-PPR1 therapeutic molecule to target pathogenic CUG repeat RNA in Myotonic Dystrophy Type 1 (DM1).
PPR Editor
Proprietary PPR-based RNA editing platform combining engineered PPR protein and a DYW enzyme domain to conduct precise C-to-U base editing within a single protein unit.
PPR Platform Technology
Proprietary RNA editing technology based on the study of PPR protein in plants, enabling targeted gene manipulation at the RNA-level such as base substitutions.
Lead therapeutic program targeting myotonic dystrophy type 1 (DM1) using RNA-targeting molecules
A preclinical development program that uses sequence-specific RNA-binding molecules to bind toxic CUG-repeat DMPK mRNA and inhibit pathogenic RNA mechanisms; delivery approaches include systemic AAV vectors.
EF-210
EF-210 is a recombinant AAV gene therapy delivering the CUG-PPR1 therapeutic molecule to target pathogenic CUG repeat RNA in Myotonic Dystrophy Type 1 (DM1).
PPR Editor
Proprietary PPR-based RNA editing platform combining engineered PPR protein and a DYW enzyme domain to conduct precise C-to-U base editing within a single protein unit.
PPR Platform Technology
Proprietary RNA editing technology based on the study of PPR protein in plants, enabling targeted gene manipulation at the RNA-level such as base substitutions.
Services
Collaborative development and licensing opportunities to apply the PPR-based RNA-editing platform across indications, including co-development arrangements and technology access.
Collaborative development and licensing opportunities to apply the PPR-based RNA-editing platform across indications, including co-development arrangements and technology access.
Expertise Areas
- RNA-targeted therapeutics development
- Gene therapy preclinical development
- RNA base editing and programmable RNA modulation
- Drug delivery system selection for nucleic-acid therapeutics (AAV, mRNA)
Key Technologies
- PPR-derived programmable RNA editing
- RNA base editing (single-nucleotide RNA substitution)
- mRNA translation activation
- Splicing modulation and exon skipping
News & Updates
Nakamura, the company's representative, will appear in a special exhibition at the Fukuoka Youth Science Museum, explaining genome editing using 'Amaou' strawberries.
Yagi discussed the development of innovative RNA tools utilizing plant PPR proteins.
The company was chosen for the prestigious J-Startup KYUSHU program, recognizing its innovative contributions to biotech.
Nakamura, the company's representative, will appear in a special exhibition at the Fukuoka Youth Science Museum, explaining genome editing using 'Amaou' strawberries.
Yagi discussed the development of innovative RNA tools utilizing plant PPR proteins.
The company was chosen for the prestigious J-Startup KYUSHU program, recognizing its innovative contributions to biotech.